Update March 5
Clinical Liver Disease - New Treatments for Hepatitis C
NYC Viral Hepatitis Monthly E-Newsletter; Hep Free NYC - March 2015 Newsletter
Clinical Liver Disease - New Treatments for Hepatitis C
NYC Viral Hepatitis Monthly E-Newsletter; Hep Free NYC - March 2015 Newsletter
March Newsletters: Children with Hepatitis C, Cirrhosis, Cure, Cost Of Treatment and More..........
Hello everyone, welcome to this month's collection of newsletters, research, and news.
In the News
Mar 3
Gilead's Harvoni gains NICE yes - but won't face funding delay - genotype 1, 4 , but not genotype 3
unlike the company's Sovaldi, which won’t be paid for until the summer
Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.
Pharmalot, Pharmalittle: We’re Reading About Gilead, Hepatitis C Drug Prices and More!!
A 30-member panel of doctors and health experts will, for the first time, address the cost effectiveness of hepatitis C drugs in updated guidelines that may change prescribing and coverage for the medicines, Bloomberg News reports....
Mar 2
Delay HCV Tx and Watch Patients Die
Even successful treatment carries risk if it is delayed, model suggests.
by Michael Smith
North American Correspondent, MedPage Today
SEATTLE -- Delaying hepatitis C (HCV) treatment in patients who also have HIV increases the risk of liver complications and death even if the therapy is successful, a researcher said.
Mar 3
Gilead's Harvoni gains NICE yes - but won't face funding delay - genotype 1, 4 , but not genotype 3
unlike the company's Sovaldi, which won’t be paid for until the summer
Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.
Pharmalot, Pharmalittle: We’re Reading About Gilead, Hepatitis C Drug Prices and More!!
A 30-member panel of doctors and health experts will, for the first time, address the cost effectiveness of hepatitis C drugs in updated guidelines that may change prescribing and coverage for the medicines, Bloomberg News reports....
Mar 2
Delay HCV Tx and Watch Patients Die
Even successful treatment carries risk if it is delayed, model suggests.
by Michael Smith
North American Correspondent, MedPage Today
SEATTLE -- Delaying hepatitis C (HCV) treatment in patients who also have HIV increases the risk of liver complications and death even if the therapy is successful, a researcher said.
(Reuters) - Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations.
Islamabad - One of the drugs being produced at this factory was Sofosbuvir sold under the brand name Sovaldi, used to treat hepatitis C, which costs a patient Rs55000 for one month of treatment and six months of treatment is required. Another drug Everlong, the registration for which was cancelled by the DRAP, was also being manufactured unlawfully at the factory.
Research
Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview
High prevalence of neuropsychiatric disorders has been reported in chronic hepatitis C virus (HCV) infected patients. Cerebrovascular disease, brain inflammatory disorders, cognitive symptoms, peripheral neuropathy, and psychiatric disturbs are among the multifaceted clinical manifestations occurring during chronic HCV infection..
Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview
High prevalence of neuropsychiatric disorders has been reported in chronic hepatitis C virus (HCV) infected patients. Cerebrovascular disease, brain inflammatory disorders, cognitive symptoms, peripheral neuropathy, and psychiatric disturbs are among the multifaceted clinical manifestations occurring during chronic HCV infection..
Cirrhosis Regression in HCV Patients After Antiviral Therapy
Liver International, March 2, 2015
Liver International, March 2, 2015
Four popular national rating systems used by consumers to judge hospitals frequently come to very different conclusions about which hospitals are the best — or worst — potentially adding to the confusion over health care quality, rather than alleviating it, a new study shows.
Worth A Click
HCV Genotypes and Treatment
Research, news and updates with a focus on treating HCV according to genotype. Information is extracted from news articles, peer-reviewed journals, as well as liver meetings/conferences, research manuscripts and interactive learning activities.
Research, news and updates with a focus on treating HCV according to genotype. Information is extracted from news articles, peer-reviewed journals, as well as liver meetings/conferences, research manuscripts and interactive learning activities.
In Case You Missed It
February 2015 edition of "HCV Next" is available online over at Healio.com. The topic this month is HCV and cirrhosis.
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, fatty liver disease and more.Table of Contents
5 QUESTIONS
A Conversation with Michael S. Saag, MD
COVER STORY
EDITORIAL
FEATURE
IN THE JOURNALS
Rheumatic Hand Manifestations Observed in Chronic HCV
Beclabuvir with PEG-IFN a-2a/Ribavirin Safely Treated HCV
HBV, HCV in Mothers Led to Increased Risk for Neurological Outcomes in Infants
Cognitive Impairment Associated with HCV in Children
Beclabuvir with PEG-IFN a-2a/Ribavirin Safely Treated HCV
HBV, HCV in Mothers Led to Increased Risk for Neurological Outcomes in Infants
Cognitive Impairment Associated with HCV in Children
PATIENT PROFILE
TREND WATCH
Added Benefit of HCV Drug Unproven Due to Insufficient Data
HCV Trial of ‘One-Shot’ Drug Continues
FDA Approves Test Used to Screen Blood for HIV and HBV, HCV
Prime Therapeutics to Supply Competing Therapies for HCV
Clinical Setbacks Integral to Long-Term Success in HCV Treatment
HCV Trial of ‘One-Shot’ Drug Continues
FDA Approves Test Used to Screen Blood for HIV and HBV, HCV
Prime Therapeutics to Supply Competing Therapies for HCV
Clinical Setbacks Integral to Long-Term Success in HCV Treatment
March Index Of Hepatitis C Newsletters
This early index does not include all March publications, updates will be shared on Twitter as additional newsletters are released.
The
HCV Advocate newsletter is a valuable resource designed to provide the
hepatitis C community with monthly updates on events, clinical research,
and education.
HCV Advocate News & Pipeline Blog
Click Here
HCV Advocate News & Pipeline Blog
Click Here
HCV Advocate Newsletter
March 2015
March 2015
Alan Franciscus, Editor-in-Chief
In this month’s column, I write about a new combination of drugs given for 6 weeks = 100% cure rate, the unfortunate rescinding of the FDA’s breakthrough therapy designation, the one-shot cure for hepatitis C that isn’t, and finally interferon as a possible part of treatment for genotype 3.
Read more...
HealthWise: Children with Hepatitis C
Lucinda K. Porter, RN
What’s it like grow up with hepatitis C? Lucinda explores this question and other issues related to children with hepatitis C.
HealthWise: Children with Hepatitis CLucinda K. Porter, RN
What’s it like grow up with hepatitis C? Lucinda explores this question and other issues related to children with hepatitis C.
Read more...
Price Wars, Treatment Outcomes, Longevity
Alan Franciscus, Editor-in-Chief
In this month’s Patients First column there’s some good news (for a change) for patients—the lower costs of medications, studies about improvements in mental health and living longer after achieving a cure.
Price Wars, Treatment Outcomes, Longevity
Alan Franciscus, Editor-in-Chief
In this month’s Patients First column there’s some good news (for a change) for patients—the lower costs of medications, studies about improvements in mental health and living longer after achieving a cure.
Read more...
Lucinda K. Porter, RN
Read about measuring patient outcomes in terms of fibrosis stage and quality of life, a study about the longer time to develop HCV antibodies in a study of men coinfected with HIV and HCV, a possible connection between HCV and Parkinson's, and HAV-related hospitalizations in the US.
Lucinda K. Porter, RN
Read about measuring patient outcomes in terms of fibrosis stage and quality of life, a study about the longer time to develop HCV antibodies in a study of men coinfected with HIV and HCV, a possible connection between HCV and Parkinson's, and HAV-related hospitalizations in the US.
February 15, 2015
In This Issue:
The Global Spread of Genotype 1
Alan Franciscus, Editor-in-Chief
The origin of hepatitis C (HCV) is unknown. The current theory is that it may have originated in horses, but while the virus found in horses is similar to the hepatitis C virus the scientific evidence linking it to hepatitis C is far from clear.
The Global Spread of Genotype 1
Alan Franciscus, Editor-in-Chief
The origin of hepatitis C (HCV) is unknown. The current theory is that it may have originated in horses, but while the virus found in horses is similar to the hepatitis C virus the scientific evidence linking it to hepatitis C is far from clear.
Read more...
Herbal Supplement Crackdown
Alan Franciscus, Editor-in-Chief
On February 3, 2015, the New York State Attorney General’s office announced that four major chains (GNC, Target, Walmart, and Walgreens) were selling herbal supplements that could not be verified to contain the labeled substances in the listed ingredients.
Herbal Supplement Crackdown
Alan Franciscus, Editor-in-Chief
On February 3, 2015, the New York State Attorney General’s office announced that four major chains (GNC, Target, Walmart, and Walgreens) were selling herbal supplements that could not be verified to contain the labeled substances in the listed ingredients.
The Five: Sleep and Insomnia
Alan Franciscus, Editor-in-Chief
A good night’s sleep is a critical component of living healthy especially with hepatitis C. Recently, the National Sleep Foundation released new recommendations for Americans of every age.
Alan Franciscus, Editor-in-Chief
A good night’s sleep is a critical component of living healthy especially with hepatitis C. Recently, the National Sleep Foundation released new recommendations for Americans of every age.
Read more...
Reallocation; ACOs; ABLE Accounts (Update on Federal Government Actions)
Jacques Chambers, CLU
This column normally focuses on benefits issues, not politics; but government actions have a large impact on benefits and the disabled persons who receive them. This month’s article takes a look at three actions by the federal government that directly affect people dealing with disability.
Reallocation; ACOs; ABLE Accounts (Update on Federal Government Actions)
Jacques Chambers, CLU
This column normally focuses on benefits issues, not politics; but government actions have a large impact on benefits and the disabled persons who receive them. This month’s article takes a look at three actions by the federal government that directly affect people dealing with disability.
Read more...
Alan Franciscus, Editor-in-Chief
Read about HCV antibody positivity in undiagnosed outpatients, and interferon therapy in hepatitis C leading to chronic type 1 diabetes.
Alan Franciscus, Editor-in-Chief
Read about HCV antibody positivity in undiagnosed outpatients, and interferon therapy in hepatitis C leading to chronic type 1 diabetes.
Read more...
Published February 26
In This Issue
Welcome to the February 2015 edition of the Liver Lowdown. Click on the links below and check out our featured stories for the month!
FEATURE: KNOW YOUR DOSE
This is the season for colds and flu and as you head to the drugstore, it is important to be aware that too much acetaminophen can be dangerous. It’s safe and effective when used as directed, but taking more than the recommended dose can lead to liver damage or worse.
READ MORE
PATIENT ADVOCATE PROFILE: A SON'S LEGACY
Justin Barney was a strapping college student. All this changed one weekend and now his mother is on a mission to warn the public about the dangers of acetaminophen when not taken as directed.
READ MORE
MEET OUR RESEARCHERS
Research is integral to the work of the American Liver Foundation and is essential to finding new ways to prevent, treat and cure liver disease. Supporting early-career scientists is critical to this effort. In 2014, the American Liver Foundation provided funding to 11 early-career scientists from some of the nation’s leading academic institutions who are making the study of liver disease their life’s work. Meet one of them.
READ MORE
HAPPENINGS
There is always a lot happening at the American Liver Foundation and in the world of liver disease. Find out what we've been up to!
READ MORE
IN THE NEWS
The American Liver Foundation is making news on topics including liver wellness, disease prevention, screening and treatment.
READ MORE
RECIPE OF THE MONTH
You have heard the old saw, “Everything in moderation.” And this month we present a somewhat decadent recipe for you to enjoy – in moderation.
READ MORE
CALENDAR OF EVENTS
ALF hosts a number of events throughout the year to support liver disease awareness. Check our events calendar and find one to participate in.
READ MORE
Check Us Out On Twitter and Facebook
HepCBC Hepatitis C Education and Prevention Society
HepCBC’s MONTHLY NEWSLETTER
The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.
February - hepc.bull -- 02 2015
March News
WHO Calls for Universal Use of 'Smart Syringes' by 2020
The World Health Organization has called for all hospitals and clinics worldwide to use “smart syringes,” which prevent a second use, by 2020.
February Review
February 26, 2015
Daclatasvir and Sovaldi Cure 97% of Hep C in Those Coinfected With HIV
Twelve weeks daclatasvir and Sovaldi offered a hep C 97 percent cure rate among those with genotypes 1 through 4 who were coinfected with HIV.
February 25, 2015
People With Hep C May Stick With Meds Better If Care Is Personalized
Clinicians treating people with hepatitis Cappear more likely to keep them adherent to the medications if they add a personal touch to care, tailoring information and feedback to specific needs.
February 23, 2015
FDA to Rescind 'Breakthrough' Status for BMS Hep C Drug Daclatasvir
The FDA intends to rescind the “breakthrough” designation for Bristol-Myers Squibb's hepatitis C therapy daclatasvir.
98% Hep C Cure Rate For Harvoni in Those Coinfected With HIV
Twelve weeks of Harvoni yielded a 98 percent hepatitis C cure rate among those with genotype 1 of the virus who are coinfected with HIV.
High Hep Cure Rates for Viekira Pak Among Those Coinfected With HIV
Viekira Pak plus ribavirin boasts a hepatitis C cure rate in the low-90 percent range among those with genotype 1 of the virus who are coinfected with HIV.
February 19, 2015
PrEP Users’ Sexually Acquired Hep C Suggests Need for Routine Testing
Evidence of sexual acquisition of hepatitis C among gay men receiving PrEP at a San Francisco clinic has prompted a call for routine testing for the virus among PrEP users.
February 18, 2015
Success for a Program to Help Get People With Hep C Into Care
A program to screen people in Philadelphia for hepatitis C and get those who test positive into specialty medical care proved successful.
February 17, 2015
People With Hep C Have High Rates of Depression and Poor Health
A large study of people with hepatitis C found high rates of depression and poor physical health. Those cured of the virus had a lower chance of depression.
February 11, 2015
ACH-3102 and Sovaldi Have 100% Hepatitis C Cure Rate in 6 Weeks
Six weeks of Achillion’s ACH-3102 and Gilead Sciences’ Sovaldi (sofosbuvir) cured 100 percent of a small trial of people with genotype 1 of hepatitis C.
February 09, 2015
Just One of the Pills in AbbVie’s Hep C Regimen Cures 95% of 1b’s
AbbVie’s combination tablet of ombitasvir, paritaprevir and ritonavir cured 95 percent of treatment-naive Japanese adults with genotype 1b of hepatitis C who did not have cirrhosis.
February 04, 2015
FDA Intends to Rescind ‘Breakthrough’ Status for Merck Hep C Therapy
The FDA has alerted Merck of its intention to rescind the “breakthrough designation” for its investigatory hepatitis C therapy grazoprevir/elbasvir (MK-5172/MK-8742).
February 02, 2015
HIV Viral Rebounds Predict Fibrosis in HCV-Coinfected People
People coinfected with HIV and hepatitis C are more likely to develop liver fibrosis if they experience an HIV viral load rebound, rather than just a blip.
Connect With Us On Twitter and Facebook
Connect With Us
February 2015 Literature Review
Advocates Unite! Conference
May 10 – 13, 2015
Learn More
Hep C Connections - Website
Our mission is to educate the general public about hepatitis C and to provide resources and support for those affected by the virus. Hep C Connection offers a helpline to answer your questions regarding hepatitis C (HCV). You can expect respect, patience & understanding, in clear, jargon-free language from our staff & volunteers. Call 1-800-522-HEPC (4372) today!
February Newsletter
In This Issue
Hep C Connection Celebrates 20 Years of Service
Upcoming Events
"The Incredible Recent Revolution in Hep C Treatment"
Patient Advocate Network
Hepatitis C news, is an online community for those living with hepatitis C. Join us for news, views and features about hep C, read the real-life experiences of our guest bloggers, and learn about living well with the condition.
New In March @ Hepatitis C News
Spotlight on… Gregg Allman
Healthy You
Be a Partner in Clinical Research
Help Others, Help Yourself
Lucinda K. Porter, RN
Author, Hepatitis C Advocate, Health Educator
Do I or Don't I Have Hepatitis C?
Hepatitis C testing can be confusing, and if you don't understand the results, you may think you have hepatitis C when you actually don't.
Hep C Treatment Clinical Trial Study with Sovaldi and GS5816 with Hep C Patient Ethel, part 1 -
Hep C Treatment Clinical Trial with Gilead’s Sovaldi and GS5816 combo brings success for stage 4 Hep C patient Ethel. Ethel shares her story this week on Life Beyond Hepatitis C in a special interview. Connie: Ethel, we are excited to hear your story with this amazing clinical trial combo and the changes it has ....
Journey Through Hep C as a Survivor
There is real hope to journey through Hep C and be a survivor. No matter where you are in your battle with Hep C, you are not alone.…
Important Website Updates
Alan Franciscus, Editor-in-Chief
We are making some important website updates to make the experience better for our audience. More information will become available as the changes are being made.
Alan Franciscus, Editor-in-Chief
We are making some important website updates to make the experience better for our audience. More information will become available as the changes are being made.
Welcome to the February 2015 edition of the Liver Lowdown
Published February 26
Welcome to the February 2015 edition of the Liver Lowdown. Click on the links below and check out our featured stories for the month!
FEATURE: KNOW YOUR DOSE
This is the season for colds and flu and as you head to the drugstore, it is important to be aware that too much acetaminophen can be dangerous. It’s safe and effective when used as directed, but taking more than the recommended dose can lead to liver damage or worse.
READ MORE
PATIENT ADVOCATE PROFILE: A SON'S LEGACY
Justin Barney was a strapping college student. All this changed one weekend and now his mother is on a mission to warn the public about the dangers of acetaminophen when not taken as directed.
READ MORE
MEET OUR RESEARCHERS
Research is integral to the work of the American Liver Foundation and is essential to finding new ways to prevent, treat and cure liver disease. Supporting early-career scientists is critical to this effort. In 2014, the American Liver Foundation provided funding to 11 early-career scientists from some of the nation’s leading academic institutions who are making the study of liver disease their life’s work. Meet one of them.
READ MORE
HAPPENINGS
There is always a lot happening at the American Liver Foundation and in the world of liver disease. Find out what we've been up to!
READ MORE
IN THE NEWS
The American Liver Foundation is making news on topics including liver wellness, disease prevention, screening and treatment.
READ MORE
RECIPE OF THE MONTH
You have heard the old saw, “Everything in moderation.” And this month we present a somewhat decadent recipe for you to enjoy – in moderation.
READ MORE
CALENDAR OF EVENTS
ALF hosts a number of events throughout the year to support liver disease awareness. Check our events calendar and find one to participate in.
READ MORE
Check Us Out On Twitter and Facebook
.
HepCBC Hepatitis C Education and Prevention Society
HepCBC’s MONTHLY NEWSLETTER
The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.
February - hepc.bull -- 02 2015
Check back for March Issue
Hep is an award-winning print and online brand for people living with and affected by viral hepatitis. Offering unparalleled editorial excellence since 2010, Hep and HepMag.com are the go-to source for educational and social support for people living with hepatitis.
March News
WHO Calls for Universal Use of 'Smart Syringes' by 2020
The World Health Organization has called for all hospitals and clinics worldwide to use “smart syringes,” which prevent a second use, by 2020.
February Review
February 26, 2015
Daclatasvir and Sovaldi Cure 97% of Hep C in Those Coinfected With HIV
Twelve weeks daclatasvir and Sovaldi offered a hep C 97 percent cure rate among those with genotypes 1 through 4 who were coinfected with HIV.
February 25, 2015People With Hep C May Stick With Meds Better If Care Is Personalized
Clinicians treating people with hepatitis Cappear more likely to keep them adherent to the medications if they add a personal touch to care, tailoring information and feedback to specific needs.
February 23, 2015FDA to Rescind 'Breakthrough' Status for BMS Hep C Drug Daclatasvir
The FDA intends to rescind the “breakthrough” designation for Bristol-Myers Squibb's hepatitis C therapy daclatasvir.
98% Hep C Cure Rate For Harvoni in Those Coinfected With HIV
Twelve weeks of Harvoni yielded a 98 percent hepatitis C cure rate among those with genotype 1 of the virus who are coinfected with HIV.
High Hep Cure Rates for Viekira Pak Among Those Coinfected With HIV
Viekira Pak plus ribavirin boasts a hepatitis C cure rate in the low-90 percent range among those with genotype 1 of the virus who are coinfected with HIV.
February 19, 2015PrEP Users’ Sexually Acquired Hep C Suggests Need for Routine Testing
Evidence of sexual acquisition of hepatitis C among gay men receiving PrEP at a San Francisco clinic has prompted a call for routine testing for the virus among PrEP users.
February 18, 2015Success for a Program to Help Get People With Hep C Into Care
A program to screen people in Philadelphia for hepatitis C and get those who test positive into specialty medical care proved successful.
February 17, 2015People With Hep C Have High Rates of Depression and Poor Health
A large study of people with hepatitis C found high rates of depression and poor physical health. Those cured of the virus had a lower chance of depression.
February 11, 2015ACH-3102 and Sovaldi Have 100% Hepatitis C Cure Rate in 6 Weeks
Six weeks of Achillion’s ACH-3102 and Gilead Sciences’ Sovaldi (sofosbuvir) cured 100 percent of a small trial of people with genotype 1 of hepatitis C.
February 09, 2015Just One of the Pills in AbbVie’s Hep C Regimen Cures 95% of 1b’s
AbbVie’s combination tablet of ombitasvir, paritaprevir and ritonavir cured 95 percent of treatment-naive Japanese adults with genotype 1b of hepatitis C who did not have cirrhosis.
February 04, 2015FDA Intends to Rescind ‘Breakthrough’ Status for Merck Hep C Therapy
The FDA has alerted Merck of its intention to rescind the “breakthrough designation” for its investigatory hepatitis C therapy grazoprevir/elbasvir (MK-5172/MK-8742).
February 02, 2015HIV Viral Rebounds Predict Fibrosis in HCV-Coinfected People
People coinfected with HIV and hepatitis C are more likely to develop liver fibrosis if they experience an HIV viral load rebound, rather than just a blip.
Connect With Us On Twitter and Facebook
Project Inform believes it is possible to create the first generation free of HIV and hepatitis C within the next decade. To achieve that dream, we focus our work in four areas: drug development, bio-medical prevention, education and health care access.
As Project Inform prepares to mark 30 years of its leadership in the fight against HIV and also hepatitis C, we would like to turn to those who have made it possible for this organization to achieve so much — our volunteers, donors, clients and staff members — to help tell our great story.
Please take a moment to submit a paragraph or two about what has made you proudest about Project Inform, its people and lifesaving work. Everything, from the profound to the hilarious, is encouraged.
We look forward to sharing these stories with PIP eNews readers and the larger community throughout 2015. Thank you!
Help Lines
HELP-4-HEP (hepatitis C helpline)
Toll-free at 1-877-435-7443 Monday–Friday, 9am–7pm (Eastern Time).
Toll-free at 1-877-435-7443 Monday–Friday, 9am–7pm (Eastern Time).
Learn more.
HIV Health InfoLine
Toll-free at 1-800-822-7422 Monday–Friday, 10am–4pm (Pacific Time), call-back service only. English only.
HIV Health InfoLine
Toll-free at 1-800-822-7422 Monday–Friday, 10am–4pm (Pacific Time), call-back service only. English only.
Connect With Us
The primary goal of the Caring Ambassadors Program is to help individuals with challenging health conditions to become ambassadors for their own health. We are here to help you—that is now and always will be our singular focus.
Monthly Pubmed Review of the most relevant research on HCV
Index
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES 1- 9
BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES 9-14
HIV/HCV COINFECTION 14-19
EPIDEMIOLOGY, DIAGNOSTICS & MISCELLANEOUS WORKS 19-24
LIVER CANCER 24-27
May 10 – 13, 2015
Learn More
Caring Ambassadors is excited to announce the release of Hep C Discussion Point™. Try this free powerful and interactive online tool for people living with hepatitis C !
Connect with us on Facebook
Connect with us on Facebook
Hep C Connections - Website
Our mission is to educate the general public about hepatitis C and to provide resources and support for those affected by the virus. Hep C Connection offers a helpline to answer your questions regarding hepatitis C (HCV). You can expect respect, patience & understanding, in clear, jargon-free language from our staff & volunteers. Call 1-800-522-HEPC (4372) today!
February Newsletter
In This Issue
Hep C Connection Celebrates 20 Years of Service
"The Incredible Recent Revolution in Hep C Treatment"
Patient Advocate Network
and more..........
Hepatitis C news, is an online community for those living with hepatitis C. Join us for news, views and features about hep C, read the real-life experiences of our guest bloggers, and learn about living well with the condition.
New In March @ Hepatitis C News
Spotlight on… Gregg Allman
Of Interest
Hunting the silent killer
Hepatitis C has a cure, but how do we find those who need it? Patrick Strudwick reports on one attempt to identify some of the estimated 100,000 undiagnosed people in the UK.
Stay connected
NYC Hep C Task Force
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.
NYC Viral Hepatitis Monthly E-Newsletter
Hep Free NYC - March 2015 Newsletter
In This Newsletter
Upcoming Events
Upcoming Conferences
New Tools & Resources
Opportunities for Patients
Job & Internship Board
Funding Board
Hepatitis C has a cure, but how do we find those who need it? Patrick Strudwick reports on one attempt to identify some of the estimated 100,000 undiagnosed people in the UK.
Stay connected
NYC Hep C Task Force
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.
NYC Viral Hepatitis Monthly E-Newsletter
Hep Free NYC - March 2015 Newsletter
In This Newsletter
Upcoming Events
Upcoming Conferences
New Tools & Resources
Opportunities for Patients
Job & Internship Board
Funding Board
NYC Health Department, February 2015
2013 NYC Hepatitis B & C Surveillance Report
To view click here
What's New?
View all newsletters, here.
By: AMY KARON, GI & Hepatology News Digital Network
To view click here
View all newsletters, here.
Subscribe to this Newsletter
Join Us
GI & Hepatology News
GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.
Read breaking news stories now: visit the GI & Hepatology News website.
Join Us
GI & Hepatology News
GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.
Read breaking news stories now: visit the GI & Hepatology News website.
In The News
March 1, 2015
Infliximab most common cause of drug-induced liver injuryBy: AMY KARON, GI & Hepatology News Digital Network
VITALS
Key clinical point: Infliximab was the most common anti–tumor necrosis factor-alpha agent linked to liver injury.
Major finding: Rates of drug-induced liver injury were highest among patients treated with infliximab (8.3%), compared with 3.7% for adalimumab and 2.3% for etanercept.
Key clinical point: Infliximab was the most common anti–tumor necrosis factor-alpha agent linked to liver injury.
Major finding: Rates of drug-induced liver injury were highest among patients treated with infliximab (8.3%), compared with 3.7% for adalimumab and 2.3% for etanercept.
Data source: Prospective study of 11 cases of drug-induced liver injury and 22 controls.
Check out - HCV HUB
Hospitals should carefully monitor equipment for hepatitis C virus contamination and the possibility of health care transmission, according to a Feb. 27 report from the Centers for Disease Control and Prevention.
Newsletter
View Current Issue (Vol. 9 No. 2 February 2015): PDF | Interactive Issue
View newsletters, here
Stay connected
View newsletters, here
Stay connected
Healthy You
A monthly newsletter from the National Institutes of Health, part of the U.S. Department of Health and Human Services
Be a Partner in Clinical Research
Help Others, Help Yourself
Whether you’re healthy or sick, young or old, male or female, you’re probably eligible to participate in clinical research. Your participation may help to improve medical care.
Better Check Your Bowels
Screening for Colon and Rectal Cancer
Screening for Colon and Rectal Cancer
No matter how busy you feel, if you’re age 50 or older you should make time to talk with your doctor about getting screened for colorectal cancer.
Read more about colorectal cancer screening.
Featured Website: National Center for Complementary and Integrative Health
ACP Internist provides news and information for internists about the practice of medicine and reports on the policies, products and activities of ACP
Current Issue - March Issue
SLEEP DISORDERS
Sussing out sleep apnea
Featured Website: National Center for Complementary and Integrative Health
The NIH center that studies complementary health approaches has a new name and Web address. Get a wealth of easy-to-understand information about complementary and integrative practices. Learn what the science says about herbal remedies, acupuncture, yoga, and more.
About 71% of U.S. adults drink alcohol. Alcohol can interact with many commonly prescribed medications, including drugs to treat pain, diabetes, and high blood pressure. Alcohol can make some medications less effective or even useless. Combining alcohol with medications may cause other side effects, such as nausea, fainting, and loss of coordination. More severe effects include internal bleeding, heart problems, and difficulty breathing. Older adults are especially at risk for alcohol-medication interactions.
Find Us On Facebook
Find Us On Facebook
ACP Internist provides news and information for internists about the practice of medicine and reports on the policies, products and activities of ACP
Current Issue - March Issue
SLEEP DISORDERS
Sussing out sleep apnea
Tuesday, March 3, 2015
Not your father's Medicare
When the Affordable Care Act (ACA) was passed in 2010, the most contentious provisions, which are still the subject of challenges in federal courts, were the establishment of state-wide insurance exchanges, the “individual mandate” that compels eligible citizens to buy insurance, and the expansion of state Medicaid programs. Less well appreciated, but arguably more important, were a wide range of reforms to the Medicare program. Summarized here, they touch on almost all aspects of the program, but I want to concentrate on just 1.
Not your father's Medicare
When the Affordable Care Act (ACA) was passed in 2010, the most contentious provisions, which are still the subject of challenges in federal courts, were the establishment of state-wide insurance exchanges, the “individual mandate” that compels eligible citizens to buy insurance, and the expansion of state Medicaid programs. Less well appreciated, but arguably more important, were a wide range of reforms to the Medicare program. Summarized here, they touch on almost all aspects of the program, but I want to concentrate on just 1.
Bloggers Corner - March 2015
Hep Blogs
Karen Hoyt - Advocate
Karen Hoyt is a blogger who has a story about hepatitis C, cirrhosis, end-stage liver disease, and liver cancer.
I Don't Want a Liver Transplant
I don't want a liver transplant. The thought of someone dying to keep me alive is more than I can bear. Of course, there are a lot of other things that I don't want. I don't want to clean the branches up from the last storm. I don't want to pay taxes or shave my legs. I don't want cancer...
Lucinda K. Porter, RN
Author, Hepatitis C Advocate, Health Educator
Do I or Don't I Have Hepatitis C?
Hepatitis C testing can be confusing, and if you don't understand the results, you may think you have hepatitis C when you actually don't.
Lucinda K. Porter
Tired of Being Tired with Hepatitis CBy Lucinda K. Porter, RN
Many of those with hepatitis C are all too familiar with being so tired that you wonder how you are going to make it through the day. Fatigue is the most common symptom of hepatitis C. It is also the most common side effect of hepatitis C treatment.
click here to continue reading..
Life Beyond Hepatitis C
Many of those with hepatitis C are all too familiar with being so tired that you wonder how you are going to make it through the day. Fatigue is the most common symptom of hepatitis C. It is also the most common side effect of hepatitis C treatment.
click here to continue reading..
Life Beyond Hepatitis C
Hep C Treatment Clinical Trial with Gilead’s Sovaldi and GS5816 combo brings success for stage 4 Hep C patient Ethel. Ethel shares her story this week on Life Beyond Hepatitis C in a special interview. Connie: Ethel, we are excited to hear your story with this amazing clinical trial combo and the changes it has ....
There is real hope to journey through Hep C and be a survivor. No matter where you are in your battle with Hep C, you are not alone.…
Only 17 more days until SPRING! Stay well, see you all soon....
Always Tina
No comments:
Post a Comment